The Indian pharmaceutical industry currently among best India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. The industry is estimated to be worth $23 billion, with both domestic and export, growing at about 14 to 15 per cent annually. Taking the leadership and expertise of connecting the pharma businesses through CPhI and P-MEC India, which is one of the most comprehensive event for the pharmaceutical industry, to the next level, UBM India recently addressed the media at an event on UBM India Pharma Awards.
“UBM India believes that these initiatives are required to pave the way for stable growth, provide universal health benefits, social and environmental safety, resulting ultimately in enhancing the global image of the Indian Pharmaceutical industry,” said Joji George, MD, UBM India.
The award ceremony, to be held on December 2, will recognise select, path-breaking initiatives undertaken by the pharmaceutical industry around key areas of quality, product design, cost management, packaging, corporate social responsibility, research & development.
Among the jury will be Dr Ajit Dangi, President and CEO, Danssen Consulting, Devinder Pal, president, Catalyst Pharma Consult, Murali Nair, partner, Ernst & Young, Kaushik Desai, director, Drug Information Association.
The Indian pharmaceutical sector has more than 10,000 registered units. The industry meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles.